Xylem Inc.
Bear Case (25th pct.)
-56.1% vs price
Base Case (Median)
-45.8% vs price
Bull Case (75th pct.)
-37.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $9.35 | -92.2% | High (40%) |
| PE Comparable | $78.56 | -34.9% | Medium (25%) |
| Growth Trajectory DCF | $64.68 | -46.4% | Medium (20%) |
| Graham Number | $65.32 | -45.9% | High (80%) |
| EV/EBITDA | $73.34 | -39.2% | Medium (20%) |
| EV/FCF | $79.38 | -34.2% | Medium (20%) |
| Earnings Power Value | $41.19 | -65.9% | High (70%) |
Based on 7 out of 8 methods, XYL appears overvalued at the current price of $120.62. The base case fair value of $65.32 implies 45.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.